---
title: "Guotai Haitong Keeps Their Buy Rating on Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291204376.md"
description: "Guotai Haitong maintained a Buy rating on Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591) with a price target of HK$16.70 in a June 27 report. The stock currently holds a Moderate Buy consensus among analysts, with an average price target of HK$22.40."
datetime: "2026-06-30T00:27:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291204376.md)
  - [en](https://longbridge.com/en/news/291204376.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291204376.md)
generator: "portal-rs"
---

# Guotai Haitong Keeps Their Buy Rating on Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591)

In a report released on June 27, from Guotai Haitong maintained a Buy rating on Guangzhou Innogen Pharmaceutical Group Co Ltd Class H, with a price target of HK$16.70.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has an analyst consensus of Moderate Buy, with a price target consensus of HK$22.40.

### Related Stocks

- [02591.HK](https://longbridge.com/en/quote/02591.HK.md)

## Related News & Research

- [Guangzhou Innogen Pharmaceutical Launches HK$50 Million H-Share Buyback Plan](https://longbridge.com/en/news/296976816.md)
- [Guangzhou Innogen Wins NMPA Nod for Adolescent Obesity Trial](https://longbridge.com/en/news/290399565.md)
- [UBS Reaffirms Their Buy Rating on NIO Inc. Class A (9866)](https://longbridge.com/en/news/298690881.md)
- [Singapore medicine group Eu Yan Sang's founding family sells bungalow for $31M](https://longbridge.com/en/news/298167922.md)
- [Gloo Holdings’ ‘Controlled Company’ Status Poses Governance Risks for Minority Shareholders](https://longbridge.com/en/news/298793962.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**